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ABSTRACT OF THESIS

LATENT CLASSES OF SYMPTOM TRAJECTORY
IN A BRIEF TREATMENT FOR BORDERLINE PERSONALITY DISORDER

It is likely that patients with BPD progress through treatment in different ways.
Characterizing symptom trajectories during treatment can facilitate the identification of
distinct treatment responses, which may be shared by subgroups of patients. Researchers
have consistently identified multiple distinct symptom trajectories among individuals
with common psychopathological conditions, but no research to date has attempted to do
so among patients with BPD. This study used latent growth mixture modeling to identify
and characterize distinct classes of symptom trajectories among patients receiving an 18week cognitive-behavioral treatment for BPD. Two distinct BPD symptom trajectories
were identified in this sample, which were primarily separated by symptom severity
throughout treatment. Patients with BPD symptoms severity above a certain threshold at
baseline therefore may not be suitable candidates for brief treatment. In addition, nonresponders reported significantly higher severity in concurrent mood disorder symptoms,
greater functional impairment, lower conscientiousness, and higher neuroticism. At
outcome, non-responders had significantly lower agreeableness. Identifying symptom
trajectories in this population may be useful in detecting patient deviation from
anticipated progress, and personalizing treatment plans. In addition, determining baseline
factors associated with certain trajectories may improve clinicians’ ability to assign
patients to optimal treatment protocols.

KEYWORDS: Trajectory, Symptom Change, Outcome, Borderline Personality Disorder,
Baseline Predictors
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CHAPTER 1. INTRODUCTION
1.1

Background
Borderline personality disorder (BPD) is a severe and heterogeneous condition

characterized by a pervasive pattern of instability in interpersonal relationships, selfimage, emotion, and impulsive behavioral responses (American Psychiatric Association
[APA], 2013). BPD is the most commonly diagnosed personality disorder across
treatment settings, occurring in 10-20% of people receiving outpatient treatment, and up
to 40% of people receiving inpatient treatment, and has a prevalence of 1.6% to 5.9% in
the general population (APA, 2013; Grant et al., 2008; Zimmerman et al., 2008). BPD is
also highly comorbid with other forms of psychopathology, especially depressive,
anxiety, and substance use disorders (Carpenter et al., 2015; Grant et al., 2008).
A diagnosis of BPD requires the endorsement of five out of nine symptoms
according to the Diagnostic and Statistical Manual of Mental Disorders (5th ed.; DSM-5),
resulting in 256 different symptom combinations (APA, 2013). Based on this definition,
two people could receive a diagnosis of BPD and share only one symptom in common.
This variability in symptom presentation may indicate variability in how people with
BPD respond to treatment (Cardona et al., 2021). For example, a person who primarily
endorses BPD symptoms of emotional instability (e.g., affective liability, inappropriate or
intense anger, feelings of emptiness) may respond to and progress through treatment
differently than a person who primarily endorses symptoms of relationship difficulties
(e.g., unstable and chaotic relationships, fear of abandonment, paranoid ideation).
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Despite this variability in symptom combinations, instability across domains is
considered a core feature of BPD, as people with BPD experience frequent fluctuations in
mood, self-image, and relationship functioning. A multitude of studies using ambulatory
assessment methodology have demonstrated that people with BPD show heightened
affective instability in daily life compared to people without the condition (Kockler et al.,
2022). For example, Tolpin et al., (2004) used daily process design to demonstrate that
individuals who have higher BPD features experience greater instability in mood and
self-esteem on a daily basis. Existing treatments for BPD are not specifically designed to
reduce symptom fluctuation but instead focus on reducing the severity of patients’
negative affectivity, or teaching adaptive coping skills to increase emotion regulation
(e.g., dialectical behavior therapy [DBT]; Linehan, 1993) or attachment insecurity (e.g.,
mentalization-based treatment [MBT]; Bateman and Fonagy, 2008). However, several
evidence-based treatments have demonstrated efficacy in reducing the symptoms of
instability that characterize this condition (Cristea et al., 2017), highlighting that
instability is an important aspect of the presentation and treatment of BPD.
Given the heterogeneity and instability that characterize BPD, it is likely that
patients with this disorder progress through treatment in different ways. Characterizing
patients’ treatment trajectories at the individual or subgroup level can facilitate the
identification of unique treatment responses, deviation from anticipated progress, and
personalized treatment plans that make treatment more efficient for a given individual.
By characterizing patients’ trajectories of symptom change in treatment, it may further be
possible to empirically link specific trajectories to better outcomes and predict these
trajectories from baseline characteristics. For example, if a patient is following a
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trajectory associated with ultimate nonresponse, clinicians may use this information to
examine the therapeutic alliance, consider patient motivation for change, or otherwise
modify their treatment plan. Similarly, if a patient is following a trajectory associated
with positive response, clinicians can be confident that the current treatment plan is
facilitating the desired change. Researchers have yet to examine specific symptom
trajectories among patients receiving treatment for BPD, though numerous researchers
have identified common symptom trajectories among patients with psychiatric conditions
that are frequently comorbid with BPD, such as post-traumatic stress disorder (PTSD),
major depressive disorder (MDD), and a variety of anxiety disorders (Currier et al., 2014;
Hartmann et al., 2018; Murphy & Smith, 2018; Owen et al., 2015; Palmer et al., 2021).
1.2

Characterizing Symptom Change in Treatment
The majority of researchers examining symptom change during treatment have

used single model curves to determine whether treatment leads to symptom change at the
group level (i.e., on average). For instance, DBT has been shown to lead to decreases in
symptoms, suicidal thoughts and behaviors, and hospitalizations on average across
several samples of patients with BPD (Cristea et al., 2017). Recently, researchers have
begun to model multiple treatment trajectories simultaneously, rather than relying on
single model curves. Modeling multiple trajectories allows for the identification of
subgroups of patients that progress through treatment on distinct paths. For example,
Owen et al. (2015) studied changes in broad psychological symptoms among nearly
11,000 patients receiving short-term treatment in 47 treatment centers in the United
States. They identified three distinct treatment trajectories: rapid change (early or late in
treatment), deterioration followed by improvement, and slow but steady improvement.
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Two of these trajectories (i.e., rapid early change and slow and steady improvement)
were replicated in an independent sample of 2,500 patients receiving short-term treatment
at a university counseling center (Palmer et al., 2021). These results provide large-scale
evidence of distinct and replicable symptom trajectories, though both studies were
conducted in naturalistic settings in which specific diagnoses were not collected.
Among patients receiving treatment for specific disorders, researchers have
consistently identified at least two classes of symptom trajectories: (1) non-responders,
who either do not meaningfully improve or initially improve before reaching a plateau
and (2) responders, who demonstrate either rapid, early improvement or steady and
consistent improvement throughout treatment (Allan et al., 2016; Behrendt-Moller et al.,
2019; Hartmann et al., 2018; Held et al., 2021; Lin & Farber, 2021; Ulvenes et al., 2021).
Beyond these two classes, findings are largely inconsistent regarding the numbers of
distinct symptom trajectories patients follow, with researchers identifying three to seven
classes, depending on the disorder and treatment setting (Currier et al., 2014; Hartmann et
al., 2018; Held et al., 2021; Murphy & Smith, 2018). Despite inconsistencies in the
specific number of symptom trajectories, these findings demonstrate that patients with a
variety of mood, anxiety, and related disorders exhibit patterns of trajectories of symptom
change, although these distinct trajectories have yet to be examined in treatments for
BPD.
1.3

Predicting Trajectories from Baseline Factors
Researchers who have identified distinct and replicable symptom trajectories in

certain disorders have explored factors that predict these trajectories at the start of
treatment. The most well-replicated predictor of symptom trajectories to date is baseline
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symptom severity. Patients with more severe symptoms of anxiety, PTSD, and depression
at the start of treatment are more likely to follow nonresponse trajectories than patients
with milder baseline symptoms (Allan et al., 2016; Elliott et al., 2005; Lin & Farber,
2021). By contrast, several researchers have examined whether demographic
characteristics are related to distinct symptom trajectories, but thus far, no consistent
demographic predictors have emerged (Chu et al., 2013; Currier et al., 2014; Heckman et
al., 2017).
In the context of specific treatment protocols, additional baseline factors have
shown promise in predicting symptom trajectories. For example, negative cognitions,
negative mood, and greater hyperarousal distinguished the “minimal response” trajectory
from other trajectories among veterans with PTSD receiving brief cognitive processing
therapy (Held et al., 2021). Among inpatients with MDD, those with greater concurrent
PTSD symptom severity, higher emotional distress, and greater fears of compassion were
more likely to follow the “deterioration before improvement” trajectory (Ulvenes et al.,
2022). Taken together, these results suggest that psychological, rather than demographic,
characteristics at baseline may be particularly useful in distinguishing unique symptom
trajectories.
As unique symptom trajectories among patients with BPD have yet to be
identified, it is unclear if any common or treatment-specific baseline factors would
predict them in this population. However, the previous research on other mental health
conditions described above point to candidate factors. For instance, baseline BPD
severity may predict membership in particular response classes, similar to studies of
depression, anxiety, and PTSD (Allan et al., 2016; Elliott et al., 2005; Lin & Farber,
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2021). People with differing levels of BPD symptom severity show differential responses
to skill use during treatment (Seow et al., 2020), and greater clinical severity has been
associated with better or poorer outcomes, depending on the treatment protocol provided
(Bateman & Fonagy, 2013; Kvarstein et al., 2019). In addition, particular BPD symptoms
(e.g., interpersonal difficulties, endorsement of suicidal behaviors) may predict treatment
trajectories, akin to hypervigilance emerging a predictor of response in PTSD samples
(Held et al., 2021). Moreover, the presence of comorbid conditions, particularly PTSD
(Ulvenes et al., 2022), may affect treatment response for patients with BPD. Finally,
researchers have suggested that treatment-specific mechanisms (e.g., negative cognitions
in cognitive processing therapy; CPT; Resick et al., 2016) can also predict patients’
symptom trajectories in treatment (Held et al., 2021). Different treatments for BPD also
specify putative mechanisms of action (e.g., emotion intolerance in DBT, mentalizing in
MBT) that could be used to potentially predict symptom trajectories.
1.4

Predicting Outcomes from Symptom Trajectories
Implicit in the definitions of symptom trajectories is that different trajectories are

associated with different treatment outcomes. Trajectories characterized by early and
rapid symptom reduction have been shown to predict positive immediate treatment
outcomes in both symptoms and global functioning regardless of the treatment provided
(Lewis et al., 2012; Lutz et al., 2009). Similarly, the occurrence of rapid symptom
decreases, referred to as sudden gains, at any point in treatment consistently predicts
positive ultimate symptom change for a variety of psychiatric conditions (Shalom &
Aderka, 2020).
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However, the majority of researchers who have examined the association between
symptom trajectories and outcomes use the same construct (e.g., total symptom severity)
to define both trajectory and outcome (Lutz et al., 2009; Schumm et al., 2013; Zeeck et
al., 2020). Using the same construct to define both trajectories and outcomes to
distinguish between responders and non-responders may lead to redundant conclusions:
patients who follow a trajectory involving a decrease in symptoms are more likely to
have lower symptom severity at the end of treatment. To avoid this redundancy, it may be
more appropriate to use separate constructs to define patients' trajectories and outcomes.
Depending on the context and problem area, a wide range of variables can represent
valued outcomes (e.g., symptom severity, quality of life, frequency of a behavior,
relationship satisfaction, functioning; Boswell, 2020). For instance, researchers
examining treatments for BPD have defined outcomes using symptoms (e.g., impulsivity,
affective liability, self-image, self-harm), emotion regulation, global functioning, and
interpersonal functioning (Cheavens et al., 2022; Finch et al., 2019; Guimond et al, 2021;
Laporte et al., 2018). Researchers have demonstrated that BPD can be conceptualized by
high neuroticism, low agreeableness, and low conscientiousness (Saulsman & Page,
2004; Samuel and Widiger, 2008). Therefore, scores on these dimensions may serve as
potential treatment outcomes. In addition, people with BPD often have high levels of
mood disorder symptoms (Dell’Osso et al., 2019). Thus, severity of concurrent mood
disorder symptoms may also be an indicator of treatment outcome among people with
BPD.
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1.5

Limitations of Treatment Research on BPD
Despite the possibility of multiple unique symptom trajectories in treatments for

BPD, no researchers to our knowledge have identified them. Several study design
characteristics may have contributed to this lack of research. First, BPD treatment studies
may be underpowered to identify distinct trajectories (Weller et al., 2020). Evidencebased treatments for BPD are delivered for up to a year (Clarkin et al., 2001; Young et
al., 2003; Linehan, 1993) which limits both the number of participants who can be
enrolled and makes more intensive assessments less feasible. For instance, many BPD
treatment studies include relatively small sample sizes (i.e., ns: 50-100), with assessments
spaced 3-4 months apart (Linehan et al., 2015; Rizvi et al., 2017; Yin et al., 2021). By
contrast, distinct symptom trajectories have been identified in treatment studies of MDD
in larger samples (i.e., ns: 50-500) with either weekly or monthly assessments (Lin &
Farber, 2021; Hartmann et al., 2018). A limited number of timepoints may reduce
researchers’ ability to identify meaningful latent classes without the use of larger sample
sizes (Weller et al., 2020). A relatively brief treatment for BPD is well-suited to both
recruit a larger sample and include more frequent assessments, which would provide
greater power to identify distinct symptom trajectories. Together, this information can
inform clinicians about whether a patient is following a symptom trajectory that is likely
to result in a poor response, thus allowing clinicians to modify treatment accordingly.
1.6

Current Study
The current study was a secondary analysis of data collected among patients

receiving an 18-session cognitive-behavioral treatment for BPD (BPD Compass; SauerZavala et al., 2022). Specifically, we used latent growth mixture modeling to explore
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potential classes of BPD symptom trajectories. We evaluated trajectories based on
empirical change during treatment (i.e., symptom severity during and at the end of
treatment) without imposing a priori specifications on the number or shape of trajectories.
Thus, we did not have hypotheses related to number and shape of trajectories, nor for the
number of participants exhibiting each pattern.
The second goal of the current study was to test whether membership in distinct
trajectory classes can be predicted by demographic factors, BPD symptom severity,
presence of comorbid conditions, and clinical characteristics (including mood symptoms,
functioning, and quality of life). Researchers have consistently found that BPD is
associated with a high prevalence of childhood trauma (Golier et al., 2003) and that there
is a high comorbidity between BPD and PTSD (Zanarini et al., 2011). People with
comorbid BPD and PTSD have poorer functioning compared to either diagnosis alone
(Pagura et al., 2010), and demonstrate less favorable response to treatment (Barnicot &
Priebe, 2013; Vignarajah & Links, 2009). Therefore, in addition to the presence of a
diagnosis of PTSD, we explored whether baseline PTSD symptom severity as a predictor
of BPD symptom trajectories. Additionally, BPD Compass is designed to target three
personality-based mechanisms that are implicated in the development and maintenance of
BPD: negative affectivity, antagonism, and disinhibition. Thus, we also examined
whether putative mechanisms relevant to the treatment (i.e., negative affectivity,
agreeableness, conscientiousness) predict trajectories. Finally, based on prior findings
that higher baseline symptom severity was associated with non-responder trajectories
(Allan et al., 2016; Elliott et al., 2005; Lin & Farber, 2021), we hypothesized that patients
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with elevated baseline symptoms will be more likely to demonstrate a symptom trajectory
resulting in nonresponse.
The third goal of the present study was to explore whether membership in a given
trajectory class predicts functioning/outcomes at the final treatment session. To overcome
the limitations of previous studies that have used the same measure to determine class
and outcomes, we examined whether certain trajectories (determined using BPD
symptom severity) predict mood disorder symptoms and the personality dimensions
relevant to BPD at each patient’s last session of treatment.
CHAPTER 2. METHOD AND MATERIALS
2.1

Participants
A sample of adult participants were recruited for this study via online

advertisements and from a general pool of people seeking treatment at a local graduate
student training clinic. People were eligible for the study if they met DSM-5 (APA, 2013)
criteria for BPD; were willing to maintain a stable dosage of psychotropic medications;
and were willing to refrain from additional non-study psychological treatment for the
duration of the study period. People were excluded if they endorsed symptoms that would
be better addressed by alternative treatments (e.g., psychotic disorders, mania within the
past year, substance use disorders necessitating a higher level of care, or acute suicide
risk). After exclusion criteria, a final sample of 40 people were included in this study.
The study was approved by the local university Institutional Review Board, and
participants provided informed consent prior to engaging in any research activities.

10

2.2

Study Treatment
The current study was a secondary data analysis of a randomized waitlist control

trial designed to evaluate BPD Compass, a novel, personality-based, 18-session treatment
for BPD (Sauer-Zavala et al, 2022). BPD Compass, which loosely stands for Cognitivebehavioral Modules for Personality Symptoms, was designed to engage the putative
mechanisms associated with the three personality dimensions most characteristic of BPD:
negative affectivity, antagonism, and disinhibition. The components of BPD Compass
were drawn from or inspired by existing treatments targeting emotion dysregulation and
impulsivity (e.g., DBT) and attachment insecurity (e.g., MBT, Schema-Focused Therapy,
[SFT]: Young et al., 2003), with added content focused on values identification.
Specific treatment components of BPD Compass were administered in modules of
3-6 weekly, individual, 50-60 minute sessions. The first module involves three sessions:
psychoeducation, values identification, and self-monitoring of emotional experiences and
their short- and long-term consequences. The second module involves four sessions
focused on cognitive interventions (e.g., cognitive restructuring, core belief
identification). The third module involves six sessions focused on behavior change (e.g.,
opposite action to emotion driven urges, assertiveness training, emotional exposures).
The last module involves four sessions focused on mindfulness skills (e.g.,
nonjudgmental emotion awareness, compassion training, urge surfing), with a final
session dedicated to preventing relapse. Sessions within the second, third, and fourth
module were focused on targets related to negative affectivity, antagonism, or
disinhibition. For instance, each session of the cognitive restructuring module was
applied to automatic thoughts related to strong negative emotions (negative affectivity),
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relationships (antagonism), or impulsive urges (disinhibition), with a final wrapup/troubleshooting session.
2.3

Study Design
Upon referral or self-referral to the study, participants completed a brief phone

screen to determine potential eligibility. Likely eligible participants then underwent a
structured diagnostic assessment, which consisted of informed consent procedures and an
interview-based diagnostic assessment to confirm study eligibility and assess baseline
clinical severity. Assessments were conducted by advanced graduate students masked to
study condition. Participants completed a battery of baseline self-report questionnaires,
including BPD symptoms, demographic factors, BPD-relevant constructs, and treatmentrelevant constructs. Following the baseline assessment, participants were randomized to
either an immediate treatment condition or an 18-week delayed treatment condition. All
study procedures (i.e., phone screens, assessments, therapy sessions) were conducted via
telehealth due to the COVID-19 pandemic.
Those in the immediate treatment condition began receiving treatment after the
baseline assessment. Participants completed weekly self-report measures of BPD
symptoms, anxiety, and depression no more than 24 hours before each session. Following
session 18, participants repeated the diagnostic assessment and self-report measures
administered at baseline. Those assigned to the delayed treatment condition began
treatment 18 weeks after their initial phone screen and diagnostic assessment. After this
waitlist period, participants completed the same diagnostic assessment and baseline selfreport battery prior to beginning treatment. Participants then began treatment, following
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the same procedures and assessment schedule as those in the immediate treatment
condition.
2.4

Measures

Treatment Trajectories
BPD Symptoms. The self-report version of the Zanarini Rating Scale for
Borderline Personality Disorder (ZAN-BPD; Zanarini et al., 2015) is a 9-item measure of
BPD symptoms over the past week. Ratings of each item range from 0 (no symptoms) to
4 (severe symptoms) and are summed to create a total score ranging from 0 to 36.
Participants completed the ZAN-BPD at baseline and before each weekly session. The
self-report ZAN-BPD was used to define BPD symptom trajectories. In the current
sample, ZAN-BPD items demonstrated good internal consistency at baseline ( = .87).
Baseline Predictors of Treatment Trajectories
Demographic Characteristics. Demographic characteristics were collected at
baseline, and include age, gender, racial background, income, education level, martial
status, and sexual orientation.
BPD Symptom Severity. Given that the self-report version of the ZAN-BPD was
used to define trajectory classes, to avoid criterion contamination, we used the summed
clinician-rated version of the ZAN-BPD as a predictor of trajectories. In the current
sample, assessors demonstrated excellent reliability on ZAN-BPD severity ratings
(Krippendorff’s a = .99, 95% CI [.97, 1.00])
Personality at Pre-Treatment. The Big Five Inventory-2 subscale (BFI-2; Soto
& John, 2017) is a 60-item measure designed to assess the Big Five personality
dimensions: openness, conscientiousness, extraversion, agreeableness, and neuroticism.
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Ratings on each item range from 1 (disagree strongly) and 5 (agree strongly) and each
subscale is averaged to create a mean score ranging from 1 to 5. Scores on personality
dimensions consistently associated with BPD (neuroticism, agreeableness, and
conscientiousness) were included as predictors of treatment trajectories. Participants
completed the BFI-2 at baseline. In the current sample, the BFI-2 items in each subscale
demonstrated good internal consistence at baseline (Neuroticism  = .86, Agreeableness
 = .85, Conscientiousness  = .87).
PTSD Symptoms. Comorbid diagnoses were assessed using the Diagnostic
Interview for Anxiety, Mood, and OCD and Related Neuropsychiatric Disorders
(DIAMOND; Tolin et al., 2018), a semi-structured clinician-rated interview. You can
pull the psychometrics and reliability from the main outcomes paper. The DIAMOND
was used to assess the presence (or absence) or PTSD. Additionally, the PTSD Checklist
for DSM-5 (PCL-5; Weathers et al., 2013) is a 20-item measures designed to assess the
severity of PTSD symptoms corresponding to the DSM-5 (APA, 2013). Ratings on each
item range from 0 (not at all) to 4 (extremely) and are summed to create a total score of
0-18, with a clinical cutoff score of 31-33. Participants who endorsed a past traumatic
event completed the PCL-5 at baseline. In the current sample, the PCL-5 items
demonstrated excellent internal consistency at baseline ( = .95).
Functioning. The Work and Social Adjustment Scale (WSAS; Mundt et al.,
2002) is a 5-item self-report measure of functional impairment experienced over the past
week. Ratings of each item range from 0 (not at all) to 8 (severe interference) and are
summed to create a total score ranging from 0 to 40. Participants completed the WSAS at
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baseline and post-treatment. In the current sample, the WSAS items demonstrated good
internal consistency at baseline ( = .85).
Quality of Life. The Quality of Life Enjoyment and Satisfaction Questionnaire
(Q-LES-Q; Endicott et al., 1993) is a 14-item self-report measure of overall satisfaction
in a variety of domains (e.g., work, mood, household activities) over the past week.
Ratings of each item range from 1 (very poor) to 5 (very good) and are summed to create
a total score ranging from 14 to 70. Participants completed the Q-LES-Q at baseline and
post-treatment. In the current sample, the WSAS items demonstrated excellent internal
consistency at baseline ( = .90).
Treatment Outcomes
Anxiety and Depression at Post-Treatment. The Overall Anxiety Severity and
Impairment Scale (OASIS; Norman et al., 2006) is a 5-item self-report measure of
anxiety symptoms over the past week. Ratings of each item range from 0 (none) to 4
(extreme) and are summed to create a total score ranging from 0 to 20, with a clinical
cutoff score of 8. Participants completed the OASIS at baseline and before to each
weekly session. The Overall Depression Severity and Impairment Scale (ODSIS; Bentley
et al., 2014) is a 5-item self-report measure of depressive symptoms over the past week.
Ratings of each item range from 0 (none) to 4 (extreme/constant) and are summed to
create a total score ranging from 0 to 20, with a clinical cutoff score of 8. Participants
completed the ODSIS at baseline and before each weekly session. In the current sample,
the OASIS and ODSIS items demonstrated excellent internal consistency at baseline
(OASIS  = .92; ODSIS  = .93).
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Personality at Post-Treatment. The Big Five Inventory-2 Extra-Short Form
(BFI-2-XS) is a 15-item measure designed to briefly assess the Big Five personality
dimensions: openness, conscientiousness, extraversion, agreeableness, and neuroticism.
Ratings on each item range from 1 (disagree strongly) and 5 (agree strongly) in each
subscale are averaged to create a mean score ranging from 1 to 5. Scores on personality
dimensions consistently associated with BPD (neuroticism, agreeableness, and
conscientiousness) were included as measures of treatment outcome at patient’s final
session. Patients completed the BFI-2-XS before each session. In the current sample, the
BFI-2-XS items in each subscale demonstrated poor-to-questionable internal consistency
at patient’s final session (Neuroticism  = .62, Agreeableness  = .61, Conscientiousness
 = .55).
2.5

Data Analytic Plan
To identify patients’ trajectories of BPD symptoms, a latent growth mixture

model (LGMM) was conducted on patients’ total BPD symptom scores at 18 time points
throughout the course of treatment, using lcmm package (Proust-Lima et al., 2017) in R
(Version 1.4; R Core Team, 2020). LGMM was chosen over other methods (i.e., cluster
analysis, group-based trajectory modeling) because LGMM can identify unique
subgroups that share a similar trajectory across a series of longitudinal scores (Nylund et
al., 2007), and has been used to identify and characterize trajectories of change in patients
receiving psychotherapy (Laurenceau et al., 2007; Lin & Farber, 2021). In addition,
LGMM allows for greater variability in trajectories within identified classes when
compared to other methods (i.e., latent class analysis). Due to the variability and
symptom fluctuation common in BPD (Cardona et al., 2021), allowing this variability
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within classes may better capture symptom trajectories within this population. The
inclusion of random effects in LGMM allows for examination of within-class variability
in addition to between-class variability, increasing the nuance of predictor effects
(Frankfort et al., 2016). The LGMM models were estimated using robust maximum
likelihood method with 100 initial stage random starts to determine if the best loglikelihood is reached, and therefore that models are not only representative of a local
maximum solution (Frankfurt et al., 2016).
To determine the number of classes of BPD symptom trajectories, we started with
a one-class model and then added one additional class in subsequent models until the
addition of more classes did not improve the model’s ability to explain changes in BPD
symptoms during treatment. Information criteria that reward parsimony (fewer
parameters) was compared for each model to determine the model fit, including Akaike
Information Criterion (AIC), Bayesian Information Criterion (BIC), Consistent AIC
(CAIC), and Sample Size Adjusted BIC (ssBIC). AIC and BIC are the most commonly
used of these criteria (Nylund et al., 2007), therefore the most weight was given to these
values, with lower values indicating better fit. In addition, several information criteria
that factor optimal entropy were examined for each model, including Classification
Likelihood Criterion (CLC) and Normalized Entropy Criterion (NEC), with lower values
indicating better fit. Finally, model entropy was examined, which is a measure of the
likelihood of being able to differentiate individuals in their respective latent classes.
Model entropy ranges from 0 to 1, with higher scores indicating better ability to
differentiate between classes. These quantitative metrics were synthesized with
theoretical considerations to determine the most appropriate model.
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Baseline Predictors of Trajectory Class Membership
Next, demographic and clinical characteristics were examined as potential
predictors of class membership. To identify predictor variables, 2 tests of association and
independent samples t-tests were conducted to examine significant differences in
predictor variables between classes (Heckman et al., 2017; Murphy & Smith, 2018; Hirai
et al., 2015).
Trajectory Class Membership Predicting Outcome
To determine whether class membership is associated with specific outcomes, a
one-way analysis of variance (ANOVA) was conducted examining differences between
classes in mood disorder symptoms and personality dimensions at each participant’s final
attended session of treatment. Measures from the final session of treatment that each
participant attended were chosen to capture information from participants who dropped
out early or otherwise did not complete post-treatment questionnaires. In addition, a oneway analysis of covariance (ANCOVA) was conducted, using first-session scores of
mood disorder symptoms and personality dimensions as a covariate, to test for significant
differences between classes in the amount of change in these outcomes during treatment.
Finally, a sensitivity analysis was conducting using G*Power version 3.1.9.6
(Faul et al., 2007), to determine the effect size that I would be able to detect given the
parameters of this study. With an alpha level of .05, results indicated that I would be able
to detect an effect size of d = 1.37.
CHAPTER 3. RESULTS
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3.1

Number and Shape of Trajectory Classes
The number of distinct BPD symptom trajectories was determined by examining

information criteria fit statistics for latent growth mixture models with one through five
classes. Values of all fit statistics for each number of classes can be found in Table 1.
Nearly all fit statistics indicated a two-class model was the best fit to the data, with the
exception of ssBIC, which indicated a three-class model solution. Visually, the addition
of a third class of BPD symptom trajectory did not result in clinically meaningful
information. Therefore, based on the majority of fit statistics and theoretical
considerations a two-class model was determined to be the best fit to capture BPD
symptom trajectories in this sample.
Figure 1 depicts the mean BPD symptom scores across treatment for each of the
two classes. People in Class 1 (high symptom starters; n = 5, 12.5%) began treatment
with significantly higher self-reported BPD symptoms (M = 24.00, SD = 4.06) than those
in Class 2 (low symptom starters; n = 35, 87.5%; M = 12.80, SD = 6.76), t(38) = 3.59, p <
.01, 95% CI [4.87, 17.52], d = 1.72. In the high symptom starter class, the highest
baseline BPD symptom severity score was 26 and the lowest was 22. In the low symptom
starter class, the highest baseline BPD symptom severity score was 21 and the lowest was
4.
In addition, high symptom starters self-reported significantly higher BPD
symptoms in their final treatment session (M = 18.60, SD = 4.72) compared to low
symptom starters (M = 7.11 SD = 4.59), t(38) = 5.21, p < .01, 95% CI [7.02, 15.95], d =
2.49. Figure 2 depicts the individual trajectory of each participant in each class, providing
further detail regarding the participant trajectories that comprise each class.
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3.2

Predictors of Trajectory Class Membership
Several demographic, clinical, and personality measures were significantly

correlated (Table 2). The strongest numerical associations were between the clinicianrated ZAN-BPD and the self-reported ZAN-BPD, r = .71, p < .01, as well as the
clinician-rated ZAN-BPD and the Q-LES-Q, r = .71, p < .01.
No demographic characteristic were significantly associated with class
membership, ps > .07 (Table 3). Participants in the high symptom starter class were
significantly more likely to have a comorbid diagnosis of generalized anxiety disorder
than those in the low symptom starter class, 2(1) = 7.73, p < .01 (Table 4). No other
comorbid diagnoses were significantly associated with membership in either class, ps >
.10.
At baseline, class membership demonstrated significant medium-to-large effects
on the majority of clinical, personality, and functional measures (Table 5). Specifically,
those in the high symptom starter class had significantly higher self-reported depression
(t(37) = 1.73, p = .04, d = .83), anxiety (t(37) = 2.08, p = .02, d = .99), and PTSD (t(37)
= 1.75, p = .04, d = .84) symptoms, as well as significantly higher clinician-rated BPD
symptoms (t(37) = 1.96, p = .03, d = .94). In addition, those in the high symptom starter
class reported significantly lower conscientiousness (t(37) = -1.82, p = .04, d = -.87) and
higher neuroticism (t(37) = 2.39, p = .01, d = 1.15). Finally, those in the high symptom
starter class also reported significantly greater functional impairment (t(37) = 2.74, p <
.01, d = 1.31) and lower quality of life (t(37) = -1.85, p = .04, d = -.89). Agreeableness
did not significantly differ between classes at baseline (t(37) =
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-1.65, p = .06, d = -.79).

3.3

Trajectory Class Membership Predicting Outcome
At the final treatment session, class membership demonstrated significant, large

effects on BPD symptom severity. Specifically, high symptom starters reported higher
BPD symptoms in their final treatment session (M = 18.60, SD = 4.72) compared to
responders (M = 7.11 SD = 4.59), t(38) = 5.21, p < .01, 95% CI [7.02, 15.95], d = 2.49.
Class membership demonstrated nonsignificant small-to-medium effects on the
majority of clinical and personality measures at the final treatment session (Table 6).
Specifically, those in the high symptom starter class reported significantly lower
agreeableness at the final treatment session (t(38) = -1.72, p = .04, d = -.83). There were
no significant mean differences between any other measure at the final attended session,
ps > .06.
When controlling for baseline scores on these measures as covariates, ANCOVA
results showed no mean differences between classes in mood disorder symptom or
personality dimensions at participant’s final attended session, ps > .08 (Table 7).
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Table 1: Information Criteria Fit Statistics for One through Five Latent Classes
Parsimony Criteria

Clustering Criteria

Classes

AIC

BIC

CAIC

ssBIC

CLC

NEC

E

1

2863.76

2868.83

2871.83

2859.44

2857.76

1.00

-

2

2853.30*

2863.43*

2869.43*

2844.66

2842.77*

0.09*

0.97*

3

2853.62

2868.82

2877.82

2840.66*

2860.88

1.14

0.71

4

2858.54

2878.81

2890.81

2841.26

2872.60

1.64

0.66

5

2862.00

2887.34

2902.34

2840.40

2872.68

1.58

0.68

*Best fit value for each information criteria.
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Table 2: Correlations Among Pre-Treatment Measures of Interest
Variable

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

1. Gender
2. Education Level
3. Marital Status

-.07
.09

-.05

-.12

.59**

-.48**

.02

.27

-.21

.24

6. ZAN-BPD-SR

-.14

-.26

.08

-.20

-.45**

7. ZAN-BPD-CR

-.22

-.30

-.13

.04

-.31

.71**

8. ODSIS

-.17

-.20

-.27

.08

-.27

.48**

.49**

9. OASIS

-.13

-.23

-.32*

.15

-.32*

.55**

.61**

.61**

10. PCL-5-SF

-.11

-.31

-.12

-.11

-.29

.54**

.61**

.44**

.58**

11. BFI-A

-.12

.10

< -.01

-.04

.27

-.24

-.42**

-.25

-.26

-.28

12. BFI-C

-.18

.21

.35*

-.25

.29

-.11

-.38

-.28

-.36*

-.03

.32*

13. BFI-N

< .01

.18

-.18

.31

-.37

.30

.51**

.28

.44**

.35*

-.29

-.23

14. WSAS

-.03

-.28

-.12

-.01

-.42**

.39*

.54**

.57**

.61**

.35*

-.37*

-.34*

4. Age
5. Trajectory Class

15. Q-LES-Q

.51**

.08
.17
.27
-.14
.30
-.50**
-.71**
-.70**
-.71**
-.42**
.41**
.49**
-.44**
-.70**
Note. ZAN-BPD-SR = Zanarini Rating Scale for Borderline Personality Disorder, Self-Reported. ZAN-BPD-CR = Zanarini Rating Scale for Borderline Personality Disorder, Clinician-Rated. ODSIS
= Overall Depression Severity and Impairment Scale. OASIS = Overall Anxiety Severity and Impairment Scale. PCL-5-SF = PTSD Checklist for DSM-5, Short Form. BFI-A = Big Five Inventory
Agreeableness Subscale. BFI-C = Big Five Inventory Conscientiousness Subscale. BFI-N = Big Five Inventory Neuroticism Subscale. WSAS = Work and Social Adjustment Scale. Q-LES-Q =
Quality of Life Enjoyment and Satisfaction Questionnaire. Gender: 0 = female, 1 = male. Trajectory Class: 1 = Non-Responders, 2 = Responders.
* p < .05, ** p < .01.
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Table 3: Demographic Characteristics in Symptom Trajectory Classes

Characteristic

Full Sample

High Symptom
Starters

Low Symptom
Starters

(n = 40)

(n = 5)

(n = 35)

n/M

%/SD

n/M

%/SD

n/M

%/SD

Gender
Male

p

1.29

.86

3

7.5

0

0

3

8.6

.46

.50

34

85.0

4

80.0

30

85.7

.11

.74

Non-binary

5

12.5

1

20.1

4

11.4

.29

.59

Transgender

1

2.5

0

0

1

2.9

.15

.70

4.50

.34

Female

Education Level
High School/GED

2

5.0

1

20.0

1

2.9

2.71

.10

20

50.0

3

60.0

17

48.6

.23

.63

Technical or
Associates Degree

6

15.0

1

20.0

5

14.3

.11

.74

4-year College

9

22.5

0

0

9

25.7

1.66

.20

Master’s Degree

3

7.5

0

0

3

8.6

.46

.50

2.76

.60

Some College

Marital Status
Married

2

5.0

0

0

2

5.7

.30

.58

Living with Partner

5

12.5

0

0

5

14.3

.82

.37

Relationship

5

12.5

1

20.0

4

11.4

.29

.59

Divorced

6

15.0

0

0

6

17.1

1.01

.32

22

55.0

4

80.0

18

51.4

1.44

.23

3.29

.35

Never married
Race

Age

χ²/t

White

38

95.0

5

100

33

94.3

.30

.58

Black

4

10.0

0

0

4

11.4

.64

.43

Latinx

3

7.5

0

0

3

8.6

.46

.50

Native American

2

5.0

1

20.0

1

2.9

2.71

.10

28.0

9.8

22.0

4.06

28.90

10.10

-1.49

.07

Note. Gender and racial categories were not mutually exclusive.
*p < .05.
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Table 4: Comorbid Diagnoses in Symptom Trajectory Classes
Full Sample

High Symptom
Starters

Low Symptom
Starters

(n = 40)

(n = 5)

(n = 35)

n

%

n

%

n

%

χ²

p

Major Depressive Disorder

11

27.5

1

20.0

10

28.6

.16

.69

Persistent Depressive
Disorder

10

25.0

1

20.0

9

25.7

.08

.78

Bipolar II Disorder

7

17.5

1

20.0

6

17.1

.25

.87

Any Mood Disorder

14

35.0

3

60.0

23

65.7

.06

.80

17

42.5

5

100.0

12

34.3

7.73

.01

8

20.0

2

40.0

6

17.1

1.43

.23

10

25.0

2

40.0

8

22.9

.69

.41

Obsessive Compulsive
Disorder

6

15.0

0

0

6

100.0

1.01

.32

Social Anxiety Disorder

15

37.5

3

60.0

12

34.3

1.23

.27

9

.23

0

0

26

74.3

1.66

.20

Premenstrual Dysphoric Disorder

6

15.0

1

20.0

5

14.3

.11

.74

Substance Use Disorder

9

22.5

2

40.0

7

20.0

1.00

.32

Bulimia

2

5.0

1

20.0

1

2.9

2.71

.10

Binge Eating Disorder

5

12.5

1

20.0

4

11.4

.29

.59

DSM-5 Disorder
Mood Disorders

Anxiety Disorders
Generalized Anxiety
Disorder
Panic Disorder
Posttraumatic Stress
Disorder

Any Anxiety Disorder

25

Table 5: Pre-Treatment Clinical and Personality Characteristics in Symptom Trajectory Classes
High Symptom

Low Symptom

Starters

Starters

(n = 5)

(n = 33)

M

SD

M

SD

t

p

d

ZAN-BPD-CR

20.20

4.32

13.47

7.44

1.96*

.03

.94

ODSIS

13.80

1.64

9.74

5.16

1.73*

.04

.83

OASIS

14.00

1.41

9.43

4.83

2.08*

.02

.99

PCL-5-SF

50.80

26.54

31.17

22.79

1.75*

.04

.84

BFI-A

3.03

.50

3.53

.63

-1.65

.06

-.79

BFI-C

2.07

.32

2.70

.77

-1.82*

.04

-.87

BFI-N

4.77

.39

4.17

.54

2.39*

.01

1.15

WSAS

30.80

3.11

18.82

9.61

2.74*

<.01

1.31

Q-LES-Q

32.20

4.49

39.94

9.11

-1.85*

.04

-.89

Pre-Treatment Measure

Note. ZAN-BPD = Zanarini Rating Scale for Borderline Personality Disorder. ODSIS = Overall Depression
Severity and Impairment Scale. OASIS = Overall Anxiety Severity and Impairment Scale. PCL-5-SF = PTSD
Checklist for DSM-5, Short Form. BFI-A = Big Five Inventory Agreeableness Subscale. BFI-C = Big Five
Inventory Conscientiousness Subscale. BFI-N = Big Five Inventory Neuroticism Subscale. WSAS = Work and
Social Adjustment Scale. Q-LES-Q = Quality of Life Enjoyment and Satisfaction Questionnaire.
*p < .05.
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Table 6: Final Session Clinical and Personality Characteristics in Symptom Trajectory Classes
High Symptom

Low Symptom Starters

Starters

(n = 34)

(n = 5)
M

SD

M

SD

t

p

d

ZAN-BPD-CR

18.60

4.72

7.11

4.59

5.21

<.01

2.49

ODSIS

10.80

2.68

7.00

5.15

1.60

.06

.77

OASIS

9.80

2.59

7.48

5.05

1.46

.16

.48

BFI-2-XS-A

2.93

.28

3.54

.77

-1.72*

.04

-.83

BFI-2-XS-C

2.54

.50

2.58

.80

-.12

.45

-.06

BFI-2-XS-N

4.34

.75

4.01

.70

.97

.17

.46

Final Session Measure

Note. ODSIS = Overall Depression Severity and Impairment Scale. OASIS = Overall Anxiety Severity and
Impairment Scale. BFI-2-XS-A = Big Five Inventory-2 Extra-Short Form Agreeableness Subscale. BFI-2-XS-C =
Big Five Inventory-2 Extra-Short Form Conscientiousness Subscale. BFI-2-XS-N = Big Five Inventory-2 ExtraShort Form Neuroticism Subscale.
* p < .05.
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Table 7: ANCOVA Descriptive Statistics and Results for Post-Test by Class and Pre-Test

Final Session Score
Observed
n
Adjusted Mean
SD
F
2
Group
Mean
Low Symptom
35
7.00
7.16
2.68 26.37
.30
Starters
ODSIS
High Symptom
5
10.80
9.71
5.16
Starters
Low Symptom
35
7.80
7.57
4.34
.10
.003
Starters
OASIS
High Symptom
5
9.80
8.12
2.59
Starters
Low Symptom
34
3.54
3.49
.77
.26
.03
Starters
BFI-2-XS-A
High Symptom
5
2.93
3.24
.28
Starters
Low Symptom
34
2.58
2.53
.80
1.96
.05
Starters
BFI-2-XS-C
High Symptom
5
2.54
2.87
.50
Starters
Low Symptom
34
4.01
4.05
.70
0
0
Starters
BFI-2-XS-N
High Symptom
5
4.33
4.05
.75
Starters
Note. ODSIS = Overall Depression Severity and Impairment Scale. OASIS = Overall Anxiety Severity and
Impairment Scale. BFI-2-XS-A = Big Five Inventory-2 Extra-Short Form Agreeableness Subscale. BFI-2-XS-C =
Big Five Inventory-2 Extra-Short Form Conscientiousness Subscale. BFI-2-XS-N = Big Five Inventory-2 ExtraShort Form Neuroticism Subscale.
ODSIS: R2 = .15, Adj. R2 = .11, adjustments based on ODSIS pre-test mean = 10.25. Homogeneity of variances
tested and not significant: F = 3.08, p > .05. OASIS: R2 = .39, Adj. R2 = .36, adjustments based on OASIS pre-test
mean = 10.00. Homogeneity of variances tested and not significant: F = 1.18, p > .05. Agreeableness: R2 = .62, Adj.
R2 = .60, adjustments based on BFI-2-XS pre-test mean = 3.42. Homogeneity of variances tested and not significant:
F = 1.28, p > .05. Conscientiousness: R2 = .60, Adj. R2 = .58, adjustments based on BFI-2-XS pre-test mean = 2.51.
Homogeneity of variances tested and not significant: F = .04, p > .05. Neuroticism: R2 = .23, Adj. R2 = .19,
adjustments based on Functioning pre-test mean = 4.59. Homogeneity of variances tested and not significant: F =
.05, p > .05.
*p < .05
Measure
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Figure 1: Mean trajectories of participants’ BPD symptom severity during 18 sessions of BPD
Compass treatment.
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Figure 2: Individual mean trajectories of participants’ BPD symptom severity during 18 sessions
of BPD Compass treatment.
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CHAPTER 4. DISCUSSION
The goal of the present study was to explore potential BPD symptom trajectory classes
among people receiving an 18-session cognitive-behavioral treatment for BPD. In addition, I also
sought to examine baseline predictors of membership in symptom trajectory classes, as well as
the effects of class membership on mood disorder symptoms and personality outcomes. As the
vast majority of researchers examining treatment trajectories have done so in samples of people
receiving treatment for mood disorders (Lin & Farber, 2021; Ulvenes et al., 2021), I aimed to
expand this research by exploring symptom trajectories in a sample of people with BPD. In this
sample, I identified two distinct BPD symptom trajectories during treatment: a low symptom
starter class and a high symptom starter class. At baseline, participants in the high symptom
starter class reported greater severity across multiple clinical measures including BPD
symptoms, were more likely to be diagnosed with comorbid generalized anxiety disorder, and
reported lower conscientiousness, higher neuroticism, and marginally lower agreeableness. At
post-treatment, high symptom starters only demonstrated significantly greater BPD symptoms
and lower agreeableness, but demonstrated medium-to-large differences in anxiety, depression,
conscientiousness, and neuroticism in the expected directions.
The identification of two trajectories in this sample is consistent with prior research
identifying classes during treatment for mood disorders, in which two diverging symptom
trajectories have consistently been reported (Hartmann et al., 2018; Held et al., 2021; Lin &
Farber, 2021; Ulvenes et al., 2021). In the current sample of people receiving treatment for BPD,
participants with higher baseline BPD severity were more likely to follow a higher symptom
trajectory and maintain relatively higher BPD symptom severity throughout treatment compared
to those in the low symptom starter class. At baseline, all participants in the low symptom starter
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class scored 21 or lower on the ZAN-BPD, whereas all participants in the high symptom starter
class scored 22 or higher, suggesting that a score of 22 may serve as a useful threshold for
predicting response to BPD Compass. Practically, patients who score below this threshold may
be good candidates for BPD Compass, whereas those scoring above this threshold may require
more time in treatment to decrease symptoms, and instead may benefit from a more specialized
or intensive treatment for BPD (e.g., DBT, MBT, Transference-Focused Therapy (TFT;
Kernberg, 1985), Schema Therapy (ST; Young et al., 2003), as has been previously noted
(Bateman and Fonagy, 2013).
4.1

Predictors of Trajectory Class Membership
To optimize and personalize treatment, it is important to identify variables that predict

membership in symptom trajectory classes. In a meta-analysis of outcomes in BPD treatment,
higher baseline BPD, depression, and general psychiatric symptom severity were associated with
greater overall symptom change during treatment (Barnicot et al., 2012). This result may be an
example of regression to the mean, a statistical mechanism in which individuals who score
further away from the group baseline average show greater treatment effects (Bland & Altman,
1994; Herzog et al., 2020). However, in the current study, the high symptom starter class
reported greater baseline severity across all clinical measures, though demonstrated less ultimate
improvement than the low symptom starter class, which is contrary to the phenomenon of
regression to the mean. It is possible that higher baseline BPD symptom severity separates high
symptom starters from the low symptom starters specifically in BPD Compass treatment, and
regression to the mean may not occur in this treatment modality. People with a greater BPD
symptom severity may also have more concurrent internalizing disorder symptoms (van Dyjke et
al., 2012; Vignarajah and Links, 2009) and a greater overall level of functional impairment
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(Conklin et al., 2006; Skodol et al., 2005), which may necessitate more intensive treatment than a
brief, weekly skill-based treatment such as BPD Compass can provide. Indeed, BPD Compass
was developed as a short-term alternative to more intensive treatment; thus, it is useful to know
how to triage patients based on their presenting severity.
Beyond symptom severity, those in the high symptom starter class also reported higher
neuroticism and lower conscientiousness at baseline than those in the low symptom starter class.
Researchers have suggested that higher levels of neuroticism may worsen treatment outcomes for
a variety of emotional disorders (Bock et al., 2010; Thibodeau et al., 2015), and that neuroticism
should be targeted specifically in individuals in treatment for emotional disorders (Barlow et al.,
2014). In addition, there is evidence that lower conscientiousness may also be associated with
poorer treatment outcome among patients with emotional disorders (Bucher et al., 2019; Quilty
et al., 2008). As higher neuroticism and lower conscientiousness are characteristic of BPD
(Saulsman & Page, 2004; Samuel and Widiger, 2008), maladaptive levels of these personality
dimensions at baseline may indicate a patient is more likely to follow a symptom trajectory that
does not end in ultimate response during brief treatment. However, I was underpowered to detect
these baseline differences, and thus these results may have limited utility.
4.2

Trajectory Class Membership Predicting Outcome
In addition to ending treatment with significantly greater BPD symptom severity,

participants in the high symptom starter symptom trajectory class reported significantly lower
agreeableness at the final treatment session. Lower agreeableness can result in a poorer
therapeutic alliance, resulting in less symptom improvement in treatments for BPD (Hirsh et al.,
2012; Zufferey et al., 2019). Though therapeutic alliance was not examined in the current study,
it is possible that high sympom starters’ lack of improvement in agreeableness contributed to
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their minimal BPD symptom change by negatively affecting the alliance with their therapists.
We encourage future researchers to test this mechanistic model with more frequent
measurements of agreeableness, the alliance, and BPD symptoms.
When controlling for baseline scores, symptom trajectory classes did not significantly
differ in anxiety, depression, neuroticism, or conscientiousness at the final treatment session.
This lack of significant differences across mood disorder symptoms at the final session was
surprising, given the large effect of trajectory class membership on BPD symptoms at this
timepoint. One possible explanation is that changes in personality disorder symptoms are
relatively distinct from changes in mood and anxiety symptoms, since mood and anxiety
symptoms may be more variable and responsive to environmental stressors than BPD symptoms.
Given that BPD Compass specifically aims to teach patients skills to address maladaptive
variants of neuroticism and conscientiousness (Sauer-Zavala et al., 2020), the lack of significant
differences between low and high symptom starter classes in these personality dimensions was
also surprising. Some researchers have found that personality dimensions remain relatively stable
over the course of acute psychotherapy (De Fruyt et al., 2006; Ferguson, 2010), which may
explain why these personality dimensions did not differ in responders and non-responders at the
final treatment session. Conversely, recent research has demonstrated that some personality
dimensions do appear more likely to change during psychotherapy, including neuroticism
(Hengartner et al., 2020; Roberts et al., 2017; Sauer-Zavala et al., 2021). While these results
suggest that personality dimensions may change in the short-term, it is possible that the 18-week
duration of BPD Compass is not sufficient for such changes to be detected. Rather, it may be that
whereas symptoms can change significantly during treatment, personality dimensions change at a
slower rate. In addition, it is possible that measurement issues contributed to this result.
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Specifically, it may be that whereas the ZAN-BPD is sensitive to change in the pathological
range, the BFI-2-XS is more sensitive to change in the normative range. Therefore, it is possible
that personality changes during treatment were not detected by the BFI-2-XS among this
population. Finally, I was underpowered in this study to detect effect sizes smaller than d = 1.37,
which may also explain the lack of significant differences in neuroticism and conscientiousness
between low and high symptom starter classes at the final treatment session.
4.3

Utilizing Symptom Trajectories in Clinical Practice
Characterizing patients’ symptom trajectories during treatment can facilitate the

identification of subgroups of treatment responses in a given population. In clinical practice, this
information can then be used to identify patient deviation from anticipated progress, and
therefore give clinicians an opportunity to personalize treatment. For example, if a patient is
identified as following a symptom trajectory likely to end in ultimate nonresponse, the clinician
has an opportunity to attempt to prevent this outcome by examining the therapeutic alliance,
revisiting the patients’ motivation for change, considering an alternative treatment modality, or
otherwise modifying their treatment plan. Similarly, if a patient is identified as following a
symptom trajectory likely to end in a positive response, the clinician can be confident that the
current method of treatment is facilitating the desired change. In addition, having the information
to predict the symptom trajectory that a given individual is likely to follow may also benefit
clinicians, as it may help them develop or adjust treatment plans.
Beyond monitoring patient progress during treatment, identifying classes of symptom
trajectories may also improve clinician’s ability to assign patients to an optimal treatment
protocol. Researchers have developed models using baseline patient characteristics to determine
the optimal treatment for individual patients, such the Personalized Advantage Index (PAI;
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DeRubeis et al., 2014), which uses baseline information to predict symptom severity at posttreatment. Similarly, as certain baseline patient characteristics may predict which symptom
trajectory a patient is likely to follow, these characteristics may be used to assign patients to the
appropriate level of care prior to treatment initiation. For example, the current study suggests that
a brief, CBT-based intervention for BPD may not be sufficient for patients who are above a
certain level of baseline symptom severity. With this information, clinicians can assign patients
who are above this level of severity to a higher level of care, thus providing a more beneficial
treatment to these patients and protecting space for patients who would benefit from brief
treatment.
4.4

Limitations
The results of this study should be considered in the context of certain limitations. First,

this study was conducted with participants receiving treatment in a single location who were
mostly white, female, and held at least a high school diploma. Replication of this study among
participants with a wider range demographic characteristics is warranted to improve
generalizability. Previous researchers have identified symptom trajectories using similar sample
sizes to that of the current study (Abbott et al. 2019, Eisenlohr-Moul et al., 2020; Lin & Farber,
2021); however, our sample size may be insufficient to accurately capture the number and shape
of possible BPD symptom trajectories. Future researchers should build on our results by
examining symptom trajectories in a larger sample to validate the number of classes identified
here. In addition, with the exception of the clinician-rated ZAN-BPD, all measures included in
analysis were self-reported, which may have introduced bias in participant responses due to
cognitive processes or social desirability (Bauhoff, 2014). Finally, the use of latent growth
mixture models results in certain inherent limitations. All group-based trajectory modeling
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generally involves some degree of uncertainty regarding the number and shape of trajectories
due to the lack of agreed-upon metrics for class enumeration. Consequently, studies often differ
in findings due to different analytical approaches (Franklin et al., 2016). In addition, researchers
have shown that when using growth mixture models, multiple trajectories can appear to be the
optimal fit even when only one group truly exists in the population (Bauer & Curran, 2003).
4.5

Conclusion
In this study examining BPD symptom trajectories in a sample of individuals receiving a

novel 18-week cognitive behavioral treatment for BPD, two distinct classes of symptom
trajectories were identified; low symptom starters and high symptom starters. These two classes
were primarily separated by BPD symptom severity, with the high symptom starter class
reporting significantly higher symptom severity at baseline, throughout treatment, and at
outcome. In addition, high symptom starters reported significantly higher severity in concurrent
mood disorder symptoms, greater functional impairment, lower conscientiousness, and higher
neuroticism. At outcome, high symptom starters had significantly lower agreeableness than
responders. These results demonstrate that distinct symptom trajectories can be identified in
patients receiving treatment for BPD, and a number of characteristics can predict which
trajectory an individual is more likely to follow. In addition, these results lend support for future
investigations into symptom trajectories in this population. If replicated, clinicians may use this
information to identify likely symptom trajectories prior to treatment, as well as identify when a
patient is following a trajectory likely to end in nonresponse, and therefore modify treatment
accordingly.

37

REFERENCES
Abbott, C. H., Zisk, A., Bounoua, N., Diamond, G. S., & Kobak, R. (2019). Predicting patterns
of treatment response and outcome for adolescents who are suicidal and
depressed. Journal of the American Academy of Child & Adolescent Psychiatry, 58(9),
897–906. doi:10.1016/j.jaac.2018.12.013
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental
disorders (5th ed.). https://doi.org/10.1176/appi.books.9780890425596
Allan, N. P., Gros, D. F., Myers, U. S., Korte, K. J., & Acierno, R. (2017). Predictors and
outcomes of growth mixture modeled trajectories across an exposure‐based PTSD
intervention with Veterans. Journal of Clinical Psychology, 73(9), 1048–1063.
doi:/10.1002/jclp.22408
Barlow, D. H., Sauer-Zavala, S., Carl, J. R., Bullis, J. R., and Ellard, K. K. (2014). The nature,
diagnosis, and treatment of neuroticism: back to the future. Clin. Psychol. Sci. 2, 344–
365. doi: 10.1177/2167702613505532
Barnicot, K., Katsakou, C., Bhatti, N., Savill, M., Fearns, N., & Priebe, S. (2012). Factors
predicting the outcome of psychotherapy for borderline personality disorder: A
systematic review. Clinical Psychology Review, 32(5), 400–412,
doi:10.1016/j.cpr.2012.04.004
Barnicot, K., & Priebe, S. (2013). Post‐traumatic stress disorder and the outcome of dialectical
behaviour therapy for borderline personality disorder. Personality and Mental
Health, 7(3), 181–190. doi:10.1002/pmh.1227
Bateman, A., & Fonagy, P. (2013). Impact of clinical severity on outcomes of mentalisationbased treatment for borderline personality disorder. British Journal of Psychiatry, 203(3),
221– 227. doi:10.1192/bjp.bp.112.121129
Bateman, A. W., & Fonagy, P. (2008). Mentalization-based treatment for BPD. Social Work in
Mental Health, 6(1–2), 187–201. doi:10.1300/J200v06n01_15
Bauer, D. J., & Curran, P. J. (2003). Distributional Assumptions of Growth Mixture Models:
Implications for Overextraction of Latent Trajectory Classes. Psychological Methods,
8(3), 338–363. doi:10.1037/1082-989X.8.3.338
Bauhoff, S. (2014). Self-Report Bias in Estimating Cross-Sectional and Treatment Effects. In:
Michalos, A.C. (eds) Encyclopedia of Quality of Life and Well-Being Research.
Springer, Dordrecht. https://doi.org/10.1007/978-94-007-0753-5_4046
Behrendt, M. I., Madsen, T., Sørensen, H. J., Sylvia, L., Friedman, E. S., Shelton, R. C.,
Bowden, C. L., Calabrese, J. R., McElroy, S. L., Ketter, T. A., Reilly, H. N. A., Gao, K.,
Thase, M., Bobo, W. V., Tohen, M., McInnis, M., Kamali, M., Kocsis, J. H.,

38

Deckersbach, T., … Nierenberg, A. A. (2019). Patterns of changes in bipolar depressive
symptoms revealed by trajectory analysis among 482 patients with bipolar
disorder. Bipolar Disorders, 21(4), 350–360. doi:10.1111/bdi.12715
Bentley, K. H., Gallagher, M. W., Carl, J. R., & Barlow, D. H. (2014). Development and
validation of the Overall Depression Severity and Impairment Scale. Psychological
Assessment, 26(3), 815–830. doi:10.1037/a0036216
Bland, J. M., & Altman, D. G. (1994). Statistic notes. BMJ, 308(6942), 1499.
https://doi.org/10.1136/bmj.308.6942.1499.
Bock, C., Bukh, J. D., Vinberg, M., Gether, U., & Kessing, L. V. (2010). The influence of
comorbid personality disorder and neuroticism on treatment outcome in first episode
depression. Psychopathology, 43(3), 197–204. doi:10.1159/000304176
Boswell, J. F. (2020). Monitoring processes and outcomes in routine clinical practice: A
promising approach to plugging the holes of the practice-based evidence
colander. Psychotherapy Research, 30(7), 829–842.
doi:10.1080/10503307.2019.1686192
Bucher, M. A., Suzuki, T., & Samuel, D. B. (2019). A meta-analytic review of personality traits
and their associations with mental health treatment outcomes. Clinical Psychology
Review, 70, 51–63. https://doi-org.ezproxy.uky.edu/10.1016/j.cpr.2019.04.002
Carpenter, R. W., Wood, P. K., & Trull, T. J. (2016). Comorbidity of borderline personality
disorder and lifetime substance use disorders in a nationally representative
sample. Journal of Personality Disorders, 30(3), 336–350.
doi:10.1521/pedi_2015_29_197
Cardona, N. D., Southward, M. W., Furbish, K., Comeau, A., & Sauer-Zavala, S. (2021).
Nomothetic and idiographic patterns of responses to emotions in borderline personality
disorder. Personality Disorders: Theory, Research, and Treatment, 12(4), 354–364. doi:
10.1037/per0000465
Cheavens, J. S., Southward, M. W., Howard, K. P., Heiy, J. E., & Altenburger, E. M. (2022).
Broad strokes or fine points: Are dialectical behavior therapy modules associated with
general or domain-specific changes? Personality Disorders: Theory, Research, and
Treatment. doi:10.1037/per0000557.supp (Supplemental)
Chu, B. C., Skriner, L. C., & Zandberg, L. J. (2013). Shape of change in cognitive behavioral
therapy for youth anxiety: Symptom trajectory and predictors of change. Journal of
Consulting and Clinical Psychology, 81(4), 573–587. doi:10.1037/a0033390
Clarkin, J. F., Foelsch, P. A., Levy, K. N., Hull, J. W., Delaney, J. C., & Kernberg, O. F. (2001).
The development of a psychodynamic treatment for patients with borderline personality

39

disorder: A preliminary study of behavioral change. Journal of Personality
Disorders, 15(6), 487–495. doi:10.1521/pedi.15.6.487.19190
Conklin, C. Z., Bradley, R., & Westen, D. (2006). Affect regulation in borderline personality
disorder. The Journal of nervous and mental disease, 194(2), 69–77.
https://doi.org/10.1097/01.nmd.0000198138.41709.4f
Cramer, V., Torgersen, S., & Kringlen, E. (2006). Personality disorders and quality of life A
population study. Comprehensive Psychiatry, 47(3), 178–184.
doi:10.1016/j.comppsych.2005.06.002
Cristea, I. A., Gentili, C., Cotet, C. D., Palomba, D., Barbui, C., & Cuijpers, P. (2017). Efficacy
of psychotherapies for borderline personality disorder: A systematic review and metaanalysis. JAMA Psychiatry, 74(4), 319–328. doi:10.1001/jamapsychiatry.2016.4287
Currier, J. M., Holland, J. M., & Drescher, K. D. (2014). Residential treatment for combatrelated posttraumatic stress disorder: identifying trajectories of change and predictors of
treatment response. PloS one, 9(7), e101741. doi:10.1371/journal.pone.0101741
De Fruyt, F., Van Leeuwen, K., Bagby, R. M., Rolland, J. P., and Rouillon, F. (2006). Assessing
and interpreting personality change and continuity in patients treated for major
depression. Psychol. Assess. 18, 71–80. doi: 10.1037/1040-3590.18.1.71
Dell’Osso, L., Cremone, I. M., Carpita, B., Dell’Oste, V., Muti, D., Massimetti, G., Barlati, S.,
Vita, A., Fagiolini, A., Carmassi, C., & Gesi, C. (2019). Rumination, posttraumatic stress
disorder, and mood symptoms in borderline personality disorder. Neuropsychiatric
Disease and Treatment, 15. doi:10.2147/NDT.S198616
DeRubeis, R. J., Cohen, Z. D., Forand, N. R., Fournier, J. C., Gelfand, L. A., & Lorenzo-Luaces,
L. (2014). The Personalized Advantage Index: translating research on prediction into
individualized treatment recommendations. A demonstration. PloS one, 9(1), e83875.
https://doi.org/10.1371/journal.pone.0083875
van Dijke, A., Ford, J., van der Hart, O., van Son, M., vander Heijden, P., & Buhring, M.
(2012). Complexposttraumatic stress disorder in patients with borderlinepersonality
disorder and somatoform disorder.PsychologicalTrauma: Theory, Research, Practice, and
Policy,4, 162–168.doi:10.1037/a0025732
Eisenlohr-Moul, T. A., Kaiser, G., Weise, C., Schmalenberger, K. M., Kiesner, J., Ditzen, B., &
Kleinstäuber, M. (2020). Are there temporal subtypes of premenstrual dysphoric
disorder?: Using group-based trajectory modeling to identify individual differences in
symptom change. Psychological Medicine, 50(6), 964–972.
doi:10.1017/S0033291719000849

40

Elliott, P., Biddle, D., Hawthorne, G., Forbes, D., & Creamer, M. (2005). Patterns of Treatment
Response in Chronic Posttraumatic Stress Disorder: An Application of Latent Growth
Mixture Modeling. Journal of Traumatic Stress, 18(4), 303–311. doi:10.1002/jts.20041
Endicott, J., Nee, J., Harrison, W., & Blumenthal, R. (1993). Quality of life enjoyment and
satisfaction questionnaire: A new measure. Psychopharmacology Bulletin, 29(2), 321–
326.
Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. (2007). G*Power 3: A flexible statistical
power analysis program for the social, behavioral, and biomedical sciences. Behavior
Research Methods, 39, 175–191. https://doi.org/10.3758/BF03193146
Ferguson, C. J. (2010). A meta-analysis of normal and disordered personality across the life
span. J. Pers. Soc. Psychol. 98, 659–667. doi: 10.1037/a0018770
Finch, E. F., Iliakis, E. A., Masland, S. R., & Choi-Kain, L. W. (2019). A meta-analysis of
treatment as usual for borderline personality disorder. Personality Disorders: Theory,
Research, and Treatment, 10(6), 491–499. doi:10.1037/per0000353
Frankfurt, S., Frazier, P., Syed, M., & Jung, K. R. (2016). Using group-based trajectory and
growth mixture modeling to identify classes of change trajectories. The Counseling
Psychologist, 44(5), 622–660. doi:10.1177/0011000016658097
Golier, J., Yehuda, R., Bierer, L. M., Mitropoulou, V., New, A. S., Schmeidler, J., Silverman, J.
M., & Siever, L. J. (2003). The Relationship of Borderline Personality Disorder to
Posttraumatic Stress Disorder and Traumatic Events. The American Journal of
Psychiatry, 160(11), 2018–2024. doi:10.1176/appi.ajp.160.11.2018
Grant, B. F., Chou, S. P., Goldstein, R. B., Huang, B., Stinson, F. S., Saha, T. D., Smith, S. M.,
Dawson, D. A., Pulay, A. J., Pickering, R. P., & Ruan, W. J. (2008). Prevalence,
correlates, disability, and comorbidity of DSM-IV borderline personality disorder:
Results from the Wave 2 National Epidemiologic Survey on Alcohol and Related
Conditions. The Journal of Clinical Psychiatry, 69(4), 533–545.
doi:10.4088/JCP.v69n0404
Guillén, V., Tormo, M. E., Fonseca-Baeza, S., Botella, C., Baños, R., García-Palacios, A., &
Marco, J. H. (2021). Resilience as a predictor of quality of life in participants with
borderline personality disorder before and after treatment. BMC Psychiatry, 21.
doi:10.1186/s12888-021-03312-0
Guimond, T. H., Varma, S., Wnuk, S. M., & McMain, S. F. (2021). A longitudinal approach to
evaluating therapist and client contributions to alliance on outcomes in borderline
personality disorder. Personality Disorders: Theory, Research, and Treatment.
doi:10.1037/per0000526

41

Gunderson, J. G., Stout, R. L., McGlashan, T. H., Shea, M. T., Morey, L. C., Grilo, C. M.,
Zanarini, M. C., Yen, S., Markowitz, J. C., Sanislow, C., Ansell, E., Pinto, A., & Skodol,
A. E. (2011). Ten-year course of borderline personality disorder: Psychopathology and
function from the collaborative longitudinal personality disorders study. Archives of
General Psychiatry, 68(8), 827–837. doi:10.1001/archgenpsychiatry.2011.37
Hartmann, A., von Wietersheim, J., Weiss, H., & Zeeck, A. (2018). Patterns of symptom change
in major depression: Classification and clustering of long term courses. Psychiatry
Research, 267, 480–489. doi:10.1016/j.psychres.2018.03.086
Heckman, T. G., Heckman, B. D., Anderson, T., Bianco, J. A., Sutton, M., & Lovejoy, T. I.
(2017). Common factors and depressive symptom relief trajectories in group teletherapy
for persons ageing with HIV. Clinical Psychology & Psychotherapy, 24(1), 139–148.
doi:10.1002/cpp.1989
Held, P., Smith, D. L., Bagley, J. M., Kovacevic, M., Steigerwald, V. L., Van Horn, R., &
Karnik, N. S. (2021). Treatment response trajectories in a three-week CPT-Based
intensive treatment for veterans with PTSD. Journal of psychiatric research, 141, 226–
232 doi:10.1016/j.jpsychires.2021.07.004
Hengartner, M. P., von Wyl, A., Heiniger Haldimann, B., & Yamanaka-Altenstein, M. (2020).
Personality traits and psychopathology over the course of six months of outpatient
psychotherapy: A prospective observational study. Frontiers in Psychology, 11.
https://doi-org.ezproxy.uky.edu/10.3389/fpsyg.2020.00174
Herzog, P., Feldmann, M., Voderholzer, U., Gärtner, T., Armbrust, M., Rauh, E., Doerr, R., Rief,
W., & Brakemeier, E.-L. (2020). Drawing the borderline: Predicting treatment outcomes
in patients with borderline personality disorder. Behaviour Research and Therapy, 133.
doi:10.1016/j.brat.2020.103692
Hirai, R., Frazier, P., & Syed, M. (2015). Psychological and sociocultural adjustment of firstyear international students: Trajectories and predictors. Journal of Counseling
Psychology, 62(3), 438–452. doi:10.1037/cou0000085
Hirsh, J. B., Quilty, L. C., Bagby, R. M., & McMain, S. F. (2012). The relationship between
agreeableness and the development of the working alliance in patients with borderline
personality disorder. Journal of Personality Disorders, 26(4), 616–627.
doi:10.1521/pedi.2012.26.4.616
Kernberg, O. F. (1985). Borderline conditions and pathological narcissism. Northvale: Jason
Aronson.
Kockler, T. D., Santangelo, P. S., Eid, M., Kuehner, C., Bohus, M., Schmaedeke, S., & EbnerPriemer, U. W. (2022). Self-esteem instability might be more characteristic of borderline
personality disorder than affective instability: Findings from an e-diary study with

42

clinical and healthy controls. Journal of Psychopathology and Clinical Science, 131(3),
301–313. doi:10.1037/abn0000731 (Supplemental)
Kvarstein, E. H., Pedersen, G., Folmo, E., Urnes, Ø., Johansen, M. S., Hummelen, B., Wilberg,
T., & Karterud, S. (2019). Mentalization‐based treatment or psychodynamic treatment
programmes for patients with borderline personality disorder – the impact of clinical
severity. Psychology and Psychotherapy: Theory, Research and Practice, 92(1), 91–111.
doi:10.1111/papt.12179
Laporte, L., Paris, J., Bergevin, T., Fraser, R., & Cardin, J. (2018). Clinical outcomes of a
stepped care program for borderline personality disorder. Personality and Mental
Health, 12(3), 252–264. doi:10.1002/pmh.1421
Laurenceau, J.-P., Hayes, A. M., & Feldman, G. C. (2007). Some methodological and statistical
issues in the study of change processes in psychotherapy. Clinical Psychology
Review, 27(6), 682–695. doi:10.1016/j.cpr.2007.01.007
Lewis, C. C., Simons, A. D., & Kim, H. K. (2012). The role of early symptom trajectories and
pretreatment variables in predicting treatment response to cognitive behavioral
therapy. Journal of Consulting and Clinical Psychology, 80(4), 525–534.
doi:10.1037/a0029131
Lutz, W., Stulz, N., & Köck, K. (2009). Patterns of early change and their relationship to
outcome and follow-up among patients with major depressive disorders. Journal of
Affective Disorders, 118(1–3), 60–68. doi:10.1016/j.jad.2009.01.019
Lin, T., & Farber, B. A. (2021). Trajectories of depression in psychotherapy: How client
characteristics predict clinical improvement. Journal of Clinical Psychology, 77(6),
1354–1370. doi:10.1002/jclp.23119
Linehan, M. M. (1993). Cognitive-behavioral treatment of borderline personality disorder.
Guilford Press.
Linehan, M. M., Korslund, K. E., Harned, M. S., Gallop, R. J., Lungu, A., Neacsiu, A. D.,
McDavid, J., Comtois, K. A., & Murray-Gregory, A. M. (2015). Dialectical behavior
therapy for high suicide risk in individuals with borderline personality disorder: A
randomized clinical trial and component analysis. JAMA Psychiatry, 72(5), 475–482.
doi:10.1001/jamapsychiatry.2014.3039
Mundt, J. C., Marks, I. M., Shear, M. K., & Greist, J. M. (2002). The Work and Social
Adjustment Scale: A simple measure of impairment in functioning. The British Journal
of Psychiatry, 180(5), 461–464. doi:10.1192/bjp.180.5.461
Murphy, D., & Smith, K. V. (2018). Treatment efficacy for veterans with posttraumatic stress
disorder: Latent class trajectories of treatment response and their predictors. Journal of
Traumatic Stress, 31(5), 753–763. doi:10.1002/jts.22333

43

Norman, S. B., Cissell, S. H., Means-Christensen, A. J., & Stein, M. B. (2006). Development and
validation of an Overall Anxiety Severity and Impairment Scale (OASIS). Depression
and Anxiety, 23(4), 245–249. doi:10.1002/da.20182
Nylund, K. L., Asparouhov, T., & Muthén, B. O. (2007). Deciding on the number of classes in
latent class analysis and growth mixture modeling: A Monte Carlo simulation
study. Structural Equation Modeling, 14(4), 535–569. doi:10.1080/10705510701575396
Owen, J., Adelson, J., Budge, S., Wampold, B., Kopta, M., Minami, T., & Miller, S. (2015).
Trajectories of change in psychotherapy. Journal of Clinical Psychology, 71(9), 817–827.
doi:10.1002/jclp.22191
Pagura, J., Stein, M. B., Bolton, J. M., Cox, B. J., Grant, B., & Sareen, J. (2010). Comorbidity of
borderline personality disorder and posttraumatic stress disorder in the US
population. Journal of Psychiatric Research, 44(16), 1190–1198.
doi:10.1016/j.jpsychires.2010.04.016
Proust-Lima, C., Philipps, V., & Liquet, B. (2015). Estimation of extended mixed models using
latent classes and latent processes: the R package lcmm. arXiv preprint
arXiv:1503.00890.
Palmer, R., Owen, J., & Frazier, P. (2020). Trajectories of changes in distress in counseling
center clients: A replication study. Psychotherapy Research.
doi:10.1080/10503307.2020.1757175
Quilty, L. C., De Fruyt, F., Rolland, J.-P., Kennedy, S. H., Rouillon, P. F., & Bagby, R. M.
(2008). Dimensional personality traits and treatment outcome in patients with major
depressive disorder. Journal of Affective Disorders, 108(3), 241–250.
doi:10.1016/j.jad.2007.10.022
Resick, P. A., Monson, C. M., & Chard, K. M. (2017). Cognitive processing therapy for PTSD:
A comprehensive manual. The Guilford Press.
R Core Team (2020). R: A language and environment for statistical computing. R Foundation for
Statistical Computing, Vienna, Austria. URL: https://www.R-project.org/
Rizvi, S. L., Hughes, C. D., Hittman, A. D., & Oliveira, P. V. (2017). Can trainees effectively
deliver dialectical behavior therapy for individuals with borderline personality disorder?
Outcomes from a training clinic. Journal of Clinical Psychology, 73(12), 1599–1611.
doi:10.1002/jclp.22467
Roberts, B. W., Luo, J., Briley, D. A., Chow, P. I., Su, R., & Hill, P. L. (2017). A systematic
review of personality trait change through intervention. Psychological Bulletin, 143(2),
117–141. doi:10.1037/bul0000088.supp (Supplemental)

44

Samuel, D. B., & Widiger, T. A. (2008). A meta-analytic review of the relationships between the
five-factor model and DSM-IV-TR personality disorders: A facet level analysis. Clinical
Psychology Review, 28(8), 1326–1342. doi:10.1016/j.cpr.2008.07.002
Saulsman, L. M., & Page, A. C. (2004). The five-factor model and personality disorder empirical
literature: A meta-analytic review. Clinical Psychology Review, 23(8), 1055–1085.
doi:10.1016/j.cpr.2002.09.001
Sauer-Zavala, S., Southward, M. W., Hood, C. O., Elhusseini, S., Fruhbauerova, M., Stumpp, N.
E., & Semcho, S. A. (2022). Conceptual development and case data for a modular,
personality-based treatment for borderline personality disorder. Personality Disorders:
Theory, Research, and Treatment. doi:10.1037/per0000520
Sauer-Zavala, S., Fournier, J. C., Jarvi Steele, S., Woods, B. K., Wang, M., Farchione, T. J., &
Barlow, D. H. (2021). Does the unified protocol really change neuroticism? Results from
a randomized trial. Psychological Medicine, 51(14), 2378–2387.
doi:10.1017/S0033291720000975
Schumm, J. A., Walter, K. H., & Chard, K. M. (2013). Latent class differences explain
variability in PTSD symptom changes during cognitive processing therapy for
veterans. Psychological Trauma: Theory, Research, Practice, and Policy, 5(6), 536–544.
doi:10.1037/a0030359 (Supplemental)
Seow, L. L. Y., Page, A. C., & Hooke, G. R. (2020). Severity of borderline personality disorder
symptoms as a moderator of the association between the use of dialectical behaviour
therapy skills and treatment outcomes. Psychotherapy Research, 30(7), 920–933.
doi:10.1080/10503307.2020.1720931
Shalom, J. G., & Aderka, I. M. (2020). A meta-analysis of sudden gains in psychotherapy:
Outcome and moderators. Clinical Psychology Review, 76.
doi:10.1016/j.cpr.2020.101827
Skodol, A. E., Pagano, M. E., Bender, D. S., Shea, M. T., Gunderson, J. G., Yen, S., Stout, R. L.,
Morey, L. C., Sanislow, C. A., Grilo, C. M., Zanarini, M. C., & McGlashan, T. H. (2005).
Stability of functional impairment in patients with schizotypal, borderline, avoidant, or
obsessive-compulsive personality disorder over two years. Psychological
Medicine, 35(3), 443–451. doi:10.1017/S003329170400354X
Soto, C. J., & John, O. P. (2017). The next Big Five Inventory (BFI-2): Developing and
assessing a hierarchical model with 15 facets to enhance bandwidth, fidelity, and
predictive power. Journal of Personality and Social Psychology, 113(1), 117–143.
doi:10.1037/pspp0000096
Soto, C. J., & John, O. P. (2017). Short and extra-short forms of the Big Five Inventory–2: The
BFI-2-S and BFI2-XS. Journal of Research in Personality, 68, 69-81.

45

Tolin, D. F., Gilliam, C., Wootton, B. M., Bowe, W., Bragdon, L. B., Davis, E., Hannan, S. E.,
Steinman, S. A., Worden, B., & Hallion, L. S. (2018). Psychometric properties of a
structured diagnostic interview for DSM-5 anxiety, mood, and obsessive-compulsive and
related disorders. Assessment, 25(1), 3–13. doi: 10.1177/1073191116638410
Tolpin, L. H., Gunthert, K. C., Cohen, L. H., & O’Neill, S. C. (2004). Borderline personality
features and instability of daily negative affect and self-esteem. Journal of
Personality, 72(1), 111–137. doi:10.1111/j.0022-3506.2004.00258
Thibodeau, M. A., Quilty, L. C., De Fruyt, F., De Bolle, M., Rouillon, F., and Bagby, R. M.
(2015). Latent classes of nonresponders, rapid responders, and gradual responders in
depressed outpatients receiving antidepressant medication and psychotherapy. Depress.
Anxiety 32, 213–220. doi: 10.1002/da.22293
Ulvenes, P., Soma, C. S., Melsom, L., & Wampold, B. E. (2022). A latent trajectory analysis of
inpatient depression treatment. Psychotherapy, 59(1), 113–124. doi:10.1037/pst0000420
Vignarajah, B., & Links, P. S. (2009). The clinical significance of co‐morbid post‐traumatic
stress disorder and borderline personality disorder: Case study and literature
review. Personality and Mental Health, 3(3), 217–224. doi:10.1002/pmh.89
Weathers F. W., Litz B. T., Keane T. M., Palmieri P. A., Marx B. P., Schnurr P. P. (2013b). The
PTSD Checklist for DSM–5 (PCL-5). Boston, MA: National Center for PTSD.
Weller, B. E., Bowen, N. K., & Faubert, S. J. (2020). Latent Class Analysis: A Guide to Best
Practice. Journal of Black Psychology, 46(4), 287–
311. https://doi.org/10.1177/0095798420930932
Young, J. E., Klosko, J. S., & Weishaar, M. E. (2003). Schema therapy: A practitioner’s guide.
Guilford Press.
Yin, Q., Selby, E. A., & Rizvi, S. L. (2021). Trajectories and processes of symptom change over
time in dialectical behavior therapy for borderline personality disorder. Behavior
Therapy. doi:10.1016/j.beth.2021.10.002
Zanarini, M. C., Frankenburg, F. R., Hennen, J., Reich, D. B., & Silk, K. R. (2005). Psychosocial
Functioning of Borderline Patients and Axis II Comparison Subjects Followed
Prospectively for Six Years. Journal of Personality Disorders, 19(1), 19–29.
doi:10.1521/pedi.19.1.19.62178
Zanarini, M. C., Frankenburg, F. R., Hennen, J., Reich, D. B., & Silk, K. R. (2004). Axis I
comorbidity in patients with borderline personality disorder: 6-year follow-up and
prediction of time to remission. The American Journal of Psychiatry, 161(11), 2108–
2114. doi:10.1176/appi.ajp.161.11.2108

46

Zanarini, M. C., Weingeroff, J. L., Frankenburg, F. R., & Fitzmaurice, G. M. (2015).
Development of the self‐report version of the Zanarini Rating Scale for Borderline
Personality Disorder. Personality and Mental Health, 9(4), 243–249. https://doiorg.ezproxy.uky.edu/10.1002/pmh.1302
Zeeck, A., von Wietersheim, J., Weiss, H., Hermann, S., Endorf, K., Lau, I., & Hartmann, A.
(2020). Self-criticism and personality functioning predict patterns of symptom change in
major depressive disorder. Frontiers in Psychiatry, 11. doi:10.3389/fpsyt.2020.00147
Zimmerman, M., Chelminski, I., & Young, D. (2008). The frequency of personality disorders in
psychiatric patients. Psychiatric Clinics of North America, 31(3), 405–420.
doi:10.1016/j.psc.2008.03.015
Zufferey, P., Caspar, F., & Kramer, U. (2019). The role of interactional agreeableness in
responsive treatments for patients with borderline personality disorder. Journal of
Personality Disorders, 33(5), 691–706. doi:10.1521/pedi_2019_33_367

47

VITAE

DOUGLAS R. TERRILL

EDUCATION
August 2013 – December 2017

Bachelor of Arts
Indiana University, Bloomington, IN

PROFESSIONAL & RESEARCH EXPERIENCE
Graduate Teaching Assistant
Statistics, Positive Psychology, Research Methods
Department of Psychology
University of Kentucky
Lexington, KY
Clinical Research Assistant
Diagnostic Interviewer
Rhode Island Hospital Department of Psychiatry
PI: Mark Zimmerman
Warren Alpert Medical School
Brown University
Providence, RI
Research Study Coordinator
Family Relationships Lab
PI: Amy Holtzworth-Munroe, PhD
Department of Psychology and Brain Sciences
Indiana University
Bloomington, IN

48

August 2021 – Present

June 2019 – August 2021
June 2019 – August 2021

February 2018 – June 2019

PUBLICATIONS
Terrill, D., Levin-Aspenson, H., & Zimmerman, M. (2022). Sudden Gains and Treatment
Outcomes Among Depressed Individuals in a Partial Hospitalization Rrogramme.
Clinical Psychology & Psychotherapy, 1–11. doi:/10.1002/cpp.2734
Terrill, D., Rodriguez-Seijas, C., Zimmerman, M. (2021). Assessing Suicidal Ideation Using a
Brief Self-Report Measure. Psychiatry Research. doi:10.1016/j.psychres.2021.113737
Zimmerman, M., Terrill, D., D’Avanzato, C., Tirpak, J. (2021). Telehealth treatment of
patients in an intensive acute care psychiatric setting during the COVID-19 pandemic:
comparative safety and effectiveness to in-person treatment. Journal of Clinical
Psychiatry. 2021;82(2):20m13815.
Zimmerman, M., Terrill, D., Ward, M., D’Avanzato, C., Tirpak, J. (2021). Telemental Health
After COVID-19: Understanding Effectiveness and Implementation across Patient
Populations while Building Provider Acceptance are the Next Steps, In Reply. Journal
of Clinical Psychiatry.

Zimmerman, M., Terrill, D., Ward, M., D’Avanzato, C., Tirpak, J. Telehealth Partial
Hospital Level of Care and Borderline Personality Disorder: Reply to Renn et
al. (2021). The Journal of Clinical Psychiatry, 82(5).
https://doi.org/10.4088/JCP.21lr14037a
Graham, A., Terrill, D., Boyd, S.I., Benjamin, I., Ward, M., Zimmerman, M. (2021) Treatment
Outcomes in a Partial Hospital Program for Patients with Social Anxiety Disorder: The
Effects of Comorbid Major Depression. American Journal of Undergraduate Research.
2021;17(4). https://doi.org/10.33697/ajur.2020.033

49

